Hyperhomocysteinemia in chronic renal failure patients: Relation to nutritional status and cardiovascular disease

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 8, 2001, Pages 734-738

  Suliman, M E ^a   Lindholm, B ^a   Barany P ^a   Bergstrom J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albumin; Cardiovascular disease; Chronic renal failure; Diabetes mellitus; Homocysteine; Malnutrition

Indexed keywords

HOMOCYSTEINE; PROTEIN; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOALBUMINEMIA; MALNUTRITION; NUTRITIONAL STATUS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTAKE; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MODELS, CHEMICAL; MUTATION; SERUM ALBUMIN;

EID: 0034820739     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.122     Document Type: Article

References (53)

1. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
2. Factors predicting malnutrition in hemodialysis patients: A cross-sectional study
3. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients
4. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes
5. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis
6. Nutrition and mortality in hemodialysis
7. Malnutrition, cardiac disease and mortality: An integrated point of view
8. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients
9. Clinical epidemiology of cardiovascular disease in chronic renal disease
10. Cardiovascular risk in uraemic patients - Is it fully explained by classical risk factors?
11. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial
12. Cardiovascular disease in chronic renal insufficiency
13. Cardiac failure in kwashiorkor
14. The myocardium in kwashiorkor
15. Myocardial lesions and heart failure in infantile malnutrition
16. Homocysteine and cardiovascular disease: Cause or effect?
17. Plasma homocysteine in renal failure
18. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients
19. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration
20. Increased plasma homocysteine concentration in patients with chronic renal failure
21. Hyperhomocysteinemia in endstage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes
22. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients
23. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients
24. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
25. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia
26. Evidence of altered homocysteine metabolism in chronic renal failure
27. Effects of high-dose folic acid and pyridoxine on plasma and erythrocyte sulfur amino acids in hemodialysis patients
28. Low whole blood and erythrocyte levels of glutathione in hemodialysis and peritoneal dialysis patients
29. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure
30. Plasma and muscle free amino acids in uremia: Influence of nutrition with amino acids
31. Sulphur amino acids in plasma and muscle in patients with chronic renal failure: Evidence for taurine depletion
32. Water soluble vitamins in chronic hemodialysis and need for supplementation
33. Inhibition of the membrane transport of folates by anions retained in uremia
34. Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis
35. Water-soluble vitamin status in patients with renal disease treated with hemodialysis or peritoneal dialysis
36. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
37. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
38. Effect of MTHFR 677C> T on plasma total homocysteine levels in renal graft recipients
39. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy
40. Total, free, and protein-bound sulphur amino acids in uraemic patients
41. Influence of hemodialysis on plasma total homocysteine concentration
42. The significance of serum homocysteine levels in diabetic patients on haemodialysis
43. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus
44. Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine metabolism in the rat
45. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
46. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
47. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
48. Hyperhomocysteinaemia: A significant risk factor for cardiovascular disease in renal transplant recipients
49. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
50. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in endstage renal disease
51. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients
52. Recent data are not in conflict with homocysteine as a cardiovascular risk factor
53. The controversy over homocysteine and cardiovascular risk